Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
Note: this event has now passed.
Join us October 14, 2021 for ECHO PITCH, a special event where five top cardiovascular health start-ups compete for funding from a $250,000 pool in front of a panel of judges and a virtual audience.
These five finalists have been selected from the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program, where they received 12 months of hands-on entrepreneurship training and mentorship.
ECHO PITCH will feature five pitches at 20 minutes each followed by a keynote speaker and concluding with the funding award announcement.
| Time | Details |
|---|---|
| 1:00 – 1:15 PM | INTRODUCTIONS |
| Prof. Christine Allen Associate Vice-President and Vice-Provost, Strategic Initiatives, University of Toronto |
|
| Dr. Mansoor Husain Executive Director, Ted Rogers Centre for Heart Research |
|
| Dr. Soror Sharifpoor Director-Strategy & Translation, Translational Biology and Engineering Program, Ted Rogers Centre for Heart Research |
|
| 1:15 – 1:55 PM | PITCH COMPETITION — SESSION 1 |
| Pitch-1: Cardian Diagnostics | |
| Pitch-2: KardioLabsAI | |
| 1:55 – 2:05 PM | BREAK |
| 2:05 – 3:05 PM | PITCH COMPETITION — SESSION 2 |
| Pitch-3: MetabolIQ | |
| Pitch-4: Nurenxy | |
| Pitch-5: TissueCraft | |
| 3:05 – 3:15 PM | BREAK |
| 3:15 – 3:50 PM | FIRESIDE CHAT |
| Dr. Sumbul Desai Vice-President of Health, Apple |
|
| Dr. Heather Ross Site Lead, Ted Rogers Centre for Heart Research Head, Division of Cardiology, Peter Munk Cardiac Centre |
|
| 3:50 – 4:00 PM | CLOSING REMARKS & AWARD ANNOUNCEMENT |
| Dr. Mansoor Husain Executive Director, Ted Rogers Centre for Heart Research |
|
| 4:00 PM | PROGRAM CLOSE |
ECHO PITCH 2021 will feature a special intimate session with a global health tech leader — Dr. Sumbul Desai, Apple’s VP of Health. This session is co-sponsored by TRANSFORM HF and our Translational Biology and Engineering Program.
Sumbul Desai, MD serves as Vice President of Health at Apple, overseeing health initiatives including clinical product development, innovative clinical partnerships and medical research. She also leads the regulatory and quality teams at Apple. Apple is also working with the best in the medical field, including Harvard T.H. Chan School of Public Health, University Health Network, Brigham and Women’s Hospital and Johns Hopkins University, to conduct landmark health studies and advance discovery with the ResearchKit and CareKit platforms. Apple recently launched its Health Sharing and Walking Steadiness features, adding to the many consumer health tools available on Apple Watch and iPhone including ECG, Irregular Heart Rhythm, Cycle Tracking and Hearing Health headphone notifications.
Dr. Desai recently served as Vice Chair of Strategy and Innovation in the Department of Medicine at Stanford Medicine, as well as Associate Chief Medical Officer at Stanford Healthcare. She also serves as Clinical Associate Professor in the Department of Medicine.
Congratulations to the five companies that participated in our 2021 ECHO program and made it to this final stage. They are:
Principal, ND Advisory Services
General Partner and Board Member, Gideon Hixon Fund
Partner, Lumira Ventures
Loretta A. Rogers Chair in Heart Function
Pfizer Chair in Cardiovascular Research
Site Lead, Ted Rogers Centre for Heart Research
Head, Division of Cardiology, Peter Munk Cardiac Centre
Professor of Medicine, University of Toronto
ECHO is a specialized hands-on training program led by veteran entrepreneurs and consultants across a variety of sectors. Its mission:
(1) Provide innovators of cardiovascular technologies with entrepreneurship training, mentorship, networking and funding opportunities;
(2) Transfer research innovations and intellectual property from academic and hospital institutions into the economy;
(3) Create more start-ups in the Canadian cardiovascular health sector.
ECHO is funded and organized by the Translational Biology and Engineering Program, at the University of Toronto and the Ted Rogers Centre for Heart Research, in partnership with the Health Innovation Hub.
